Upstate Partners with CXR Biosciences
to Develop Drug-Screening Tests

Upstate Group, a Serologicals subsidiary, and CXR Biosciences plan to co-develop a series of in vitro tests to aid in the early-stage drug-discovery process, the companies said last week.

Upstate Group will partner with Dundee, Scotland-based CXR to develop the drug toxicity and metabolism screens to profile compounds in various cell-based and in vitro assays, the companies said.

Financial details were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.